Floatz logo

GLUCOSE, ANHYDROUS

Metabolic Syndrome

Aphaia Pharma US LLCSmall moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

57 Active assets in the Metabolic Syndrome cohort.

Asset / SponsorPhaseRating
Lipitor
Seoul National University Hospital
Phase 4BBB
Metformin
Islamabad Medical and Dental College
Phase 4BBB
Pioglitazone
Philip Kern
Phase 4BBB
OLMESARTAN MEDOXOMIL
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Phase 4BBB
Rosuvastatin
Hamdard University
Phase 4BBB

View all 50 →

Same molecule, other indications

GLUCOSE, ANHYDROUS is also rated in:

Liver FailureDormant
BB
Indicative ·
68 / 100
View asset →
Critical IllnessDormant
BB
Indicative ·
67 / 100
View asset →
injuryDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →